IPOs: window open, price isn’t
IPO flow stayed active, but nobody was paying up out of goodwill. Buyers are there. They’re just waiting for numbers that clear.
- Sinda launched an IPO of 17.75 million shares, another test of how much private-to-public multiple compression investors will take without blinking.
- Lime (LIME)—backed by Uber Technologies—filed for an IPO to raise $180.9 million, putting “show me the model” underwriting back on the desk.
With no macro data steering the tape, the issue was supply: can new paper clear without immediately trading heavy. The answer was mixed, and the message was clean—issuance is possible, but pricing power is not. “Story” deals still have to earn their valuation, and crowded growth lanes are where the discount shows up first.
Corporate moves: signals over stories
A few management items landed as process signals more than fundamental catalysts. That still matters when investors are allergic to drift.
- Rayonier Advanced Materials (RYAM) traded up after naming a new CEO while its strategic review continues. The market is voting for decisiveness—asset sales, restructuring, tighter execution—anything other than a review that turns into a long-running series.
- Eastplats said its CFO will leave in July 2026. It’s far out, but finance-seat stability becomes a real variable the minute refinancing or capex moves from hypothetical to scheduled.
- Lithium Africa appointed Thomas Benson as CEO, a straightforward governance update in a capital-sensitive commodity corner where credibility is a funding input.
None of this changes the world. It does change how people price follow-through.
Deals and industrial AI
The biggest capital allocation headline was simple:
- AbbVie (ABBV) was flat after announcing a $10.9 billion acquisition of Apogee Therapeutics for an experimental atopic dermatitis treatment.
Flat is information. It means the street is shelving the argument—fit, differentiation, integration—until trial data and a commercial narrative do some work. Strategically, it’s the same theme: big pharma would rather buy time and growth in immunology/inflammation than wait for internal R&D to hit deadlines.
Two other updates were more plumbing than hype:
- Fervo Energy partnered with Nvidia and PNNL on geothermal digital twin technology—AI pointed at a problem where uncertainty is expensive. Model the subsurface better, drill smarter, and you waste less time and money on bad surprises.
- AXT completed a deal with Casela to reduce export risk, a plain compliance/supply-chain move aimed at keeping shipments moving in a world that keeps adding friction to cross-border trade.
Rates backdrop: selectivity stays
- AMC (AMC) was flat even after reporting over 4.8 million weekend ticket sales tied to ‘Toy Story 5’. Traffic helps the optics, but nobody rerated the equity on a weekend print. Leverage and cash-flow durability are still the gate.
Policy chatter floated by without turning into a trade:
- Alan Greenspan died at 100, prompting retrospectives and not much else.
- The Bank of England published its final stablecoin policy draft with more lenient rules, mildly supportive for payments/crypto infrastructure sentiment.
The real positioning input was rates framing. Bank of America projected no Fed cuts until 2028 and 25 bp hikes in September, October, and December, taking rates to 4.25%–4.50% (per Aditya Bhave). Maybe that path happens, maybe it doesn’t. The point is the market keeps getting handed higher-for-longer reference cases, and the pressure lands where duration and funding needs are highest: IPOs, long-duration growth, and anything that depends on friendly capital markets.
What mattered
- IPOs are coming; clearing price is still the fight.
- Management moves helped when they implied action, not process.
- ABBV wrote a big check; investors withheld the verdict.
- Higher-for-longer talk kept the market selective, not brave.